ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

NCT00170846 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

394

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Transplantation

Interventions

DRUG: Everolimus (RAD001)
DRUG: Calcineurin Inhibitors (CNI)
DRUG: Mycophenolate acid (MPA)/Azathioprine (AZA)
DRUG: Steroids

Sponsor

Novartis Pharmaceuticals